Illustrations Doliprane Sanofi - Lisieux

Illustrations Doliprane Sanofi - Lisieux

The Doliprane medication production site of French multinational pharmaceutical and healthcare company Sanofi, in Lisieux, northern France, on October 14, 2024. Sanofi said it entered into negotiations with US private equity firm Clayton Dubilier Rice CR.R for the potential sale of a controlling 50 percent stake in its subsidiary Opella, which produces Doliprane, the best-selling drug in France. Photos taken during the French Minister for the Economy, Finance and Industry Antoine Armand's visit. Photo by Franck Castel/ABACAPRESS.COM

  • Product Code
  • ILEA003447232
  • Registered date
  • 2024/10/14 00:00:00
  • Credit
  • Abaca Press / Kyodo News Images
  • Media source
  • Castel Franck/ABACA
  • Media size
  • 5568 × 3712 pixel
  • Resolution
  • 299 dpi
  • Deployment size
  • 2.88(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Government Demands Guarantees For Doliprane Production In France

    Government Demands Guarantees For Doliprane Production In France

    Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
      Government Demands Guarantees For Doliprane Production In France

      Government Demands Guarantees For Doliprane Production In France

      Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
        Government Demands Guarantees For Doliprane Production In France

        Government Demands Guarantees For Doliprane Production In France

        Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
          Government Demands Guarantees For Doliprane Production In France

          Government Demands Guarantees For Doliprane Production In France

          Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
            Government Demands Guarantees For Doliprane Production In France

            Government Demands Guarantees For Doliprane Production In France

            Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
              Government Demands Guarantees For Doliprane Production In France

              Government Demands Guarantees For Doliprane Production In France

              Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                Government Demands Guarantees For Doliprane Production In France

                Government Demands Guarantees For Doliprane Production In France

                Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                  Government Demands Guarantees For Doliprane Production In France

                  Government Demands Guarantees For Doliprane Production In France

                  Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                    Government Demands Guarantees For Doliprane Production In France

                    Government Demands Guarantees For Doliprane Production In France

                    Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                      Government Demands Guarantees For Doliprane Production In France

                      Government Demands Guarantees For Doliprane Production In France

                      Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM